Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer

Weill Cornell Medical College - New York - Presbyterian Hospital, New York

Penn State Milton S Hershey Medical Center, Hershey

Local Institution - 663, Großhansdorf

Local Institution - 692, Madrid

Local Institution - 691, Madrid

Local Institution - 694, Málaga

University Cancer and Blood Center, LLC, Athens

Local Institution - 672, Udine

Associates in Oncology and Hematology, Chattanooga

Local Institution - 673, Bologna

Local Institution - 674, Parma

Local Institution - 651, Saint-Herblain

Local Institution - 664, Essen

Local Institution - 697, Valencia

Local Institution - 696, Valencia

Local Institution - 653, Lille

Local Institution - 603, St Louis

Local Institution - 661, Löwenstein

Millennium Oncology, Houston

UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco

Local Institution - 652, Villejuif

Hospital of Central Connecticut Gynecologic Oncology, New Britain

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

Local Institution - 642, Ottawa

Local Institution - 641, Montreal

Local Institution - 693, Barcelona

Local Institution - 695, Barcelona

Local Institution - 630, London

Local Institution - 634, Bebington, Wirral

Local Institution - 633, Birmingham

Local Institution - 635, London

Local Institution - 636, Manchester

Local Institution - 632, Newcastle upon Tyne

Local Institution - 631, Oxford